Background
Methods
Patients
Covariates
Definition of cardiovascular events
Statistical analysis
Results
Incidence of cardiovascular events
N = 207 | |
---|---|
Age, years, mean (±SD) | 39.5 ± 13.2 |
Female sex, n (%) | 174 (84.1) |
Hypertension, n (%) | 100 (48.3) |
Use of antihypertensive drugs, n (%) | 100 (48.3) |
Systolic BP, mmHg, mean (±SD) | 129.3 ± 16.1 |
Diastolic BP, mmHg, mean (±SD) | 75.6 ± 12.6 |
Diabetes mellitus, n (%) | 19 (9.2) |
Smoking, n (%) | 18 (8.7) |
Total cholesterol, mg/dl, mean (±SD) | 180.8 ± 41.0 |
Triglycerides, mg/dl, mean (±SD) | 112.6 ± 66.4 |
HDL cholesterol, mg/dl, mean (±SD) | 56.1 ± 17.0 |
LDL cholesterol, mg/dl, mean (±SD) | 102.2 ± 32.7 |
Framingham risk score, %, median (IQR)a | 4.1 (2.5–8.0) |
BMI, kg/m2, mean (±SD) | 22.5 ± 3.1 |
Hemoglobin, g/dl, mean (± SD) | 12.3 ± 1.5 |
Anemia, n (%) | 84 (40.6) |
ESR, mm/h, median (IQR) | 40.0 (20.0–67.0) |
CRP, mg/l, median (IQR) | 4.0 (1.0–22.0) |
Type of vascular involvement, n (%) | |
I | 48 (23.2) |
IIA | 23 (11.1) |
IIB | 36 (17.4) |
III | 8 (3.9) |
IV | 11 (5.3) |
V | 81 (39.1) |
Pulmonary artery involvement, n (%) | 16 (7.7) |
Aortic regurgitation, n (%) | 61 (29.5) |
Use of glucocorticoids, n (%) | |
None-to-low dose | 85 (41.1) |
Medium-to-high dose | 122 (58.9) |
Use of MTX, n (%) | 126 (60.9) |
Use of AZA, n (%) | 38 (18.4) |
Use of aspirin, n (%) | 123 (59.4) |
Use of statins, n (%) | 123 (59.4) |
Cardiovascular events, n (%) | 41 (19.8) |
Coronary arterial events | 23 (11.1) |
Cerebrovascular events | 15 (7.2) |
Congestive heart failure | 3 (1.4) |
Comparison between patients who did and did not develop cardiovascular events
CV events not occurred (N = 166) | CV events occurred (N = 41) | P value | |
---|---|---|---|
Age, years, mean (±SD) | 38.5 ± 13.4 | 43.6 ± 11.8 | 0.028 |
Female sex, n (%) | 138 (83.1) | 36 (87.8) | 0.464 |
Hypertension, n (%) | 75 (45.2) | 25 (61.0) | 0.070 |
Use of antihypertensive drugs, n (%) | 75 (45.2) | 25 (61.0) | 0.070 |
Systolic BP, mmHg, mean (± SD) | 128.9 ± 15.8 | 130.9 ± 17.0 | 0.477 |
Diastolic BP, mmHg, mean (± SD) | 75.2 ± 12.5 | 76.9 ± 13.2 | 0.439 |
Diabetes mellitus, n (%) | 11 (6.6) | 8 (19.5) | 0.029 |
Smoking, n (%) | 12 (7.2) | 6 (14.6) | 0.210 |
Total cholesterol, mg/dl, mean (± SD) | 182.9 ± 40.4 | 172.9 ± 42.6 | 0.167 |
Triglycerides, mg/dl, mean (± SD) | 108.6 ± 57.8 | 127.6 ± 91.1 | 0.209 |
HDL cholesterol, mg/dl, mean (± SD) | 57.3 ± 17.1 | 51.2 ± 15.7 | 0.040 |
LDL cholesterol, mg/dl, mean (± SD) | 103.8 ± 32.4 | 96.2 ± 33.8 | 0.183 |
Framingham risk score, %, median (IQR)a | 3.9 (2.4–7.1) | 5.5 (2.9–9.7) | 0.119 |
BMI, kg/m2, mean (± SD) | 22.5 ± 3.3 | 22.7 ± 2.7 | 0.702 |
Hemoglobin, g/dl, mean (± SD) | 12.3 ± 1.5 | 12.3 ± 1.3 | 0.980 |
Anemia, n (%) | 66 (39.8) | 18 (43.9) | 0.629 |
ESR, mm/h, median (IQR) | 39.0 (20.5–68.5) | 41.0 (20.0–66.3) | 0.717 |
CRP, mg/l, median (IQR) | 4.1 (1.0–23.1) | 3.6 (1.0–15.2) | 0.908 |
Type of vascular involvement, n (%) | |||
I | 42 (25.3) | 6 (14.6) | 0.147 |
IIA | 19 (11.4) | 4 (9.8) | > 0.999 |
IIB | 32 (19.3) | 4 (9.8) | 0.150 |
III | 7 (4.2) | 1 (1.6) | > 0.999 |
IV | 11 (6.6) | 0 (0.0) | 0.126 |
V | 55 (33.1) | 26 (63.4) | < 0.001 |
Pulmonary artery involvement, n (%) | 13 (7.8) | 3 (7.3) | > 0.999 |
Aortic regurgitation, n (%) | 44 (26.5) | 17 (41.5) | 0.060 |
Use of glucocorticoids, n (%) | |||
None-to-low dose | 66 (39.8) | 19 (46.3) | 0.443 |
Medium-to-high dose | 100 (60.2) | 22 (53.7) | |
Use of MTX, n (%) | 108 (65.1) | 18 (43.9) | 0.013 |
Use of AZA, n (%) | 33 (19.9) | 5 (12.2) | 0.255 |
Use of aspirin, n (%) | 94 (56.6) | 29 (70.7) | 0.100 |
Use of statins, n (%) | 97 (58.4) | 26 (63.4) | 0.561 |
Estimation of risk of cardiovascular events according to TAK disease-specific factors
Univariable analysis | Multivariable analysisa | |||
---|---|---|---|---|
Unadjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value | |
BMI | 1.031 (0.926–1.146) | 0.579 | 0.905 (0.796–1.029) | 0.129 |
Anemia | 0.880 (0.468–1.654) | 0.691 | 0.924 (0.464–1.838) | 0.821 |
ESR | 1.001 (0.991–1.011) | 0.878 | 0.996 (0.985–1.008) | 0.551 |
CRP | 0.995 (0.986–1.005) | 0.326 | 0.993 (0.982–1.003) | 0.183 |
Vascular involvement type | ||||
Types other than V | 1.000 (reference) | 1.000 (reference) | ||
Type V | 2.741 (1.443–5.205) | 0.002 | 2.852 (1.474–5.518) | 0.002 |
Pulmonary artery involvement | 1.011 (0.311–3.288) | 0.985 | 0.717 (0.193–2.655) | 0.618 |
Aortic regurgitation | 1.341 (0.703–2.558) | 0.373 | 1.024 (0.505–2.077) | 0.947 |
Use of glucocorticoids | ||||
None-to-low dose | 1.000 (reference) | 1.000 (reference) | ||
Medium-to-high dose | 0.780 (0.414–1.471) | 0.443 | 1.030 (0.523–2.030) | 0.932 |
Use of MTX | 0.474 (0.253–0.887) | 0.020 | 0.515 (0.268–0.993) | 0.047 |
Use of AZA | 0.592 (0.231–1.513) | 0.273 | 0.768 (0.278–2.122) | 0.611 |
Use of aspirin | 1.763 (0.880–3.532) | 0.110 | 1.426 (0.695–2.925) | 0.333 |
Use of statins | 1.220 (0.640–2.327) | 0.546 | 0.789 (0.391–1.592) | 0.508 |